Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Takrolimus C:D-förhållande uppmätt i njurtransplanterade mottagare som behandlats med depotläkemedel en gång dagligen (TaC:Drop)

3 november 2026 uppdaterad av: Edward Geissler

Multicenter, öppen etikett, randomiserad, tvåarmad, parallell grupp, överlägsenhetsförsök för att bedöma biotillgänglighet och genomförbarhet av två takrolimusformuleringar en gång dagligen, Envarsus® jämfört med Advagraf™, administrerad till njurtransplanterade mottagare

The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Detaljerad beskrivning

This clinical trial aims to compare the bioavailability and practicability of two alternative once-daily formulations of tacrolimus in patients who have received either a first or second kidney transplant and require prophylactic immunosuppressive treatment to prevent allograft rejection. Trial participants are randomised within 7 days prior to kidney transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus (test arm) or Advagraf (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to measure a dose-normalised trough level (concentration/dose, C/D ratio) as an estimate of tacrolimus bioavailability.

The primary objective is to demonstrate that the C/D ratio of tacrolimus measured in kidney transplant recipients treated with Envarsus® (test drug) is superior to (higher than) the C/D ratio measured in patients treated with Advagraf™ (comparator drug) at 12 weeks post-transplantation. The trial also aims to compare the practicability (handling) of these two once-daily drug formulations using a series of pharmacokinetic parameters that will measure the speed with which therapeutic blood trough levels are attained and the ease with which stable blood trough levels are maintained over time.

Secondarily, TaC:Drop aims to explore the relationship between the early C/D ratio measured at 12 weeks post-transplantation and later clinical outcomes measured until three years post-transplantation. The study aims to investigate whether a superior pharmacokinetic drug profile is associated with fewer and milder dose-dependent drug toxicities and superior kidney graft function, as measured by long-term safety and efficacy parameters.

Drug pharmacokinetics will be explored in greater detail during a sub-study designed to profile the peak blood concentration of Envarsus® and Advagraf™ at 12 weeks post-transplantation in patients who volunteer to provide three additional blood samples at two-hour intervals after drug intake on the day of the 12-week trial visit. Participation in this sub-study is voluntary and available to all trial centres and all trial patients.

Studietyp

Interventionell

Inskrivning (Faktisk)

322

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Aachen, Tyskland, 52074
        • University Hospital Aachen, Department of General, Visceral and Transplant Surgery
      • Berlin, Tyskland, 10117
        • Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care
      • Bochum, Tyskland, 44892
        • Knappschaft Clinic, University Hospital Bochum, Department of Surgery
      • Dresden, Tyskland, 01307
        • University Hospital Dresden, Division of Nephrology
      • Hamburg, Tyskland, 20251
        • University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology)
      • Hanover, Tyskland, 30625
        • Hannover Medical School, Department of General, Visceral and Transplant Surgery
      • Jena, Tyskland, 07747
        • University Hospital Jena, Internal Medicine III, Nephrology
      • Mainz, Tyskland, 55131
        • University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology)
      • Mannheim, Tyskland, 68167
        • University Hospital Mannheim, Medical Clinic V
      • Munich, Tyskland, 81377
        • LMU University Hospital Munich, Department of General, Visceral and Transplant Surgery
      • Münster, Tyskland, 48149
        • University Hospital Münster, Medical Clinic D
      • Regensburg, Tyskland, 93053
        • University Hospital Regensburg, Department of Nephrology
      • Würzburg, Tyskland, 97080
        • University Hospital Würzburg, Medical Clinic I, Department of Nephrology

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Signed and dated written informed consent
  2. Adult (≥18 years old) male or female
  3. Renal insufficiency necessitating kidney transplantation and approved to receive a first or second kidney allograft from a living or deceased organ donor
  4. ABO blood type compatible with the donor kidney
  5. Able to swallow an oral formulation of tacrolimus in tablet or capsule form

Exclusion Criteria:

  1. Multi-organ transplantation
  2. Any previous solid organ transplantation (other than a first kidney allograft)
  3. For recipients of a second kidney transplant: loss of first kidney transplant within 2 years after transplantation owing to immunological reasons or recurrence of the underlying renal disease
  4. Patient and/or donor is positive for active HCV, HBV or HIV infection
  5. History of any malignancy that could not be curatively treated
  6. Ongoing abuse of drugs or alcohol
  7. Signs of advanced liver disease or any signs of liver decompensation
  8. Ongoing uncontrolled systemic infection
  9. Severe diarrhoea, vomiting, active peptic ulcer, previous bariatric surgery, or any other gastrointestinal disorder that may affect absorption of tacrolimus
  10. Planned or foreseeable use of cyclosporine, belatacept or any tacrolimus preparation other than Envarsus® or Advagraf™
  11. Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf™, and/or to any other macrolides
  12. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
  13. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless using a highly-effective method of contraception
  14. Participation in another interventional clinical trial in the time period starting from 4 weeks prior to randomisation and throughout the entire trial period
  15. Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule
  16. Inability to freely give informed consent (e.g. individuals under legal guardianship)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Envarsus

Participants take prolonged-release tacrolimus tablets (Envarsus) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.

Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

Andra namn:
  • Envarsus
Aktiv komparator: Advagraf

Participants take prolonged-release tacrolimus capsules (Advagraf) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.

Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

Andra namn:
  • Advagraf

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)
Tidsram: 12 weeks after kidney transplantation

To calculate C/D ratio, "concentration" is the blood trough level of tacrolimus measured in a blood sample collected immediately prior to drug dosing on the day of the 12-week trial visit and "dose" is the daily dose taken by the patient on the day prior to the visit. C/D ratio is measured as a surrogate for tacrolimus bioavailability (i.e. systemic exposure per mg of drug). The primary endpoint uses a blood trough level reading that is measured in a central laboratory.

12 weeks after kidney transplantation

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Andel patienter med dalvärden lägre, inom eller högre än målintervallet
Tidsram: 4 dagar, 14 dagar, 28 dagar och 12 veckor efter njurtransplantation
4 dagar, 14 dagar, 28 dagar och 12 veckor efter njurtransplantation
Genomsnittlig dalnivå för takrolimus och variabilitet mellan patienter (intervall) av dalnivåer för takrolimus
Tidsram: 4 dagar, 14 dagar, 28 dagar och 12 veckor efter njurtransplantation
4 dagar, 14 dagar, 28 dagar och 12 veckor efter njurtransplantation
Genomsnittlig daglig dos av takrolimus och variabilitet mellan patienter (intervall) av daglig dos av takrolimus
Tidsram: 4 dagar, 14 dagar, 28 dagar och 12 veckor efter njurtransplantation
4 dagar, 14 dagar, 28 dagar och 12 veckor efter njurtransplantation
Variabilitet inom patienten av C/D-förhållande och daglig dos
Tidsram: Mätt över tidpunkterna: dag 4, dag 14, dag 28 och vecka 12
Mätt över tidpunkterna: dag 4, dag 14, dag 28 och vecka 12
Incidensfrekvens av orsaksbiopsier
Tidsram: 12 veckor efter njurtransplantation
12 veckor efter njurtransplantation
Incidensfrekvens av akuta avstötningsepisoder som kräver behandling
Tidsram: 12 veckor efter njurtransplantation
12 veckor efter njurtransplantation
Incidensfrekvens av steroidresistenta episoder av biopsibevisad akut avstötning
Tidsram: 12 veckor och 1 år efter njurtransplantation
12 veckor och 1 år efter njurtransplantation
Förekomst av CMV- och BKV-infektion (inklusive organmanifestation, om relevant)
Tidsram: 12 veckor och 1 år efter njurtransplantation
12 veckor och 1 år efter njurtransplantation
Förekomst, typ, svårighetsgrad och allvarlighetsgrad av biverkningar (AR)
Tidsram: 12 veckor och 3 år efter njurtransplantation
12 veckor och 3 år efter njurtransplantation
Blodtryck
Tidsram: 12 veckor och 1, 2, 3 år efter njurtransplantation
12 veckor och 1, 2, 3 år efter njurtransplantation
Förekomst av gastrointestinala störningar som kräver diagnostisk utredning
Tidsram: 12 veckor och 3 år efter njurtransplantation
12 veckor och 3 år efter njurtransplantation
Återfall av primär njursjukdom
Tidsram: 12 veckor och 3 år efter njurtransplantation
12 veckor och 3 år efter njurtransplantation
Förekomst av de novo DSA
Tidsram: Upptäcks inom det första året efter njurtransplantation
Upptäcks inom det första året efter njurtransplantation
Doser och varaktighet av glukokortikosteroidbehandling
Tidsram: 12 veckor och 1, 2, 3 år efter njurtransplantation
12 veckor och 1, 2, 3 år efter njurtransplantation
Incidens och tid för att studera behandlingsavbrott
Tidsram: 3 år efter njurtransplantation
3 år efter njurtransplantation
Incidens, tid till och orsak till att patienten drar sig ur studien
Tidsram: 3 år efter njurtransplantation
3 år efter njurtransplantation
Time to reach the first trough level in target range
Tidsram: Time period measured in days, assessed within the first 2 weeks after kidney transplantation

Reaching the target range is defined as two consecutive readings within the initial target range of 5-12 ng/ml; time is measured to the date of the first in-range reading

Time period measured in days, assessed within the first 2 weeks after kidney transplantation
Tacrolimus concentration/dose (C/D) ratio
Tidsram: 4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation

The secondary endpoint using C/D ratio data takes a blood trough level reading that is measured in the local laboratory at the trial site.

4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
Treatment failure rate
Tidsram: 12 weeks and 1, 2, 3 years after kidney transplantation

A composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or re-transplantation), or death (from any cause)

12 weeks and 1, 2, 3 years after kidney transplantation
Time to treatment failure after transplantation
Tidsram: Measured until 3 years after kidney transplantation

Treatment failure is a composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or pre-emptive re-transplantation), or death (from any cause)

Measured until 3 years after kidney transplantation
Incidence rate, severity and time to clinically-confirmed biopsy-proven acute rejection
Tidsram: 12 weeks and 1, 2, 3 years after kidney transplantation

Clinically-confirmed biopsy-proven acute rejection requires both a clinical diagnosis of rejection by an investigator and a histopathological diagnosis of rejection in a for-cause biopsy. Subclinical rejection diagnosed in a protocol biopsy is therefore excluded from this definition.

12 weeks and 1, 2, 3 years after kidney transplantation
Incidence rate of graft failure
Tidsram: 12 weeks and 1, 2, 3 years after kidney transplantation

Graft failure is defined as initiation of renal dialysis or pre-emptive re-transplantation

12 weeks and 1, 2, 3 years after kidney transplantation
Mortality rate
Tidsram: 12 weeks and 1, 2, 3 years after kidney transplantation

Mortality rate measures death from any cause

12 weeks and 1, 2, 3 years after kidney transplantation
Graft function measured by eGFR (estimated glomerular filtration rate)
Tidsram: 4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation

eGFR calculated according to the CKD-EPI formula

4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
Incidence rate of delayed graft function
Tidsram: Measurable within the first 2 weeks after kidney transplantation

Delayed graft function is defined as the need for more than one episode of dialysis after transplantation

Measurable within the first 2 weeks after kidney transplantation
Incidence rate of primary non-function of the renal allograft
Tidsram: Measurable within the first 12 weeks after kidney transplantation

Primary non-function is defined as the necessity for ongoing chronic dialysis

Measurable within the first 12 weeks after kidney transplantation
Incidence of hepatotoxicity
Tidsram: 12 weeks and 1, 2, 3 years after kidney transplantation

Hepatotoxicity is defined as GPT or GOT levels ≥ 2.5 x upper limit of normal range

12 weeks and 1, 2, 3 years after kidney transplantation
Incidence of de novo tremor
Tidsram: 12 weeks and 3 years after kidney transplantation

Incidence and severity of tremor based on medical assessment by the investigator

12 weeks and 3 years after kidney transplantation
Incidence of new onset diabetes mellitus after transplantation (NODAT)
Tidsram: 12 weeks and 1, 2, 3 years after kidney transplantation

NODAT is defined as HbA1c ≥ 6.5% or 47.5 mmol/mol or fasting plasma glucose ≥ 126 mg/dl on two separate occasions

12 weeks and 1, 2, 3 years after kidney transplantation
Patient-reported health-related quality-of-life measured using the Kidney Transplant Questionnaire-34 (KTQ-34)
Tidsram: 12 weeks and 3 years after kidney transplantation

The KTQ-34 is a renal transplantation-specific instrument that measures quality-of-life in five dimensions. It is a self-administered questionnaire that is completed in writing by the trial patients.

12 weeks and 3 years after kidney transplantation
Dose of mycophenolate
Tidsram: 12 weeks and 1, 2, 3 years after kidney transplantation

Including both mycophenolate mofetil and mycophenolic acid

12 weeks and 1, 2, 3 years after kidney transplantation

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Samarbetspartners

Utredare

  • Huvudutredare: Bernhard Banas, MD, University Hospital Regensburg

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

9 mars 2024

Primärt slutförande (Faktisk)

4 februari 2026

Avslutad studie (Beräknad)

1 november 2028

Studieregistreringsdatum

Först inskickad

12 februari 2024

Först inskickad som uppfyllde QC-kriterierna

12 februari 2024

Första postat (Faktisk)

20 februari 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • TaC:Drop
  • 2023-503531-18-00 (Annan identifierare: EUCT Number)
  • 2023 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera